Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy.

Area of Science:

• Cardiovascular Research
• Immunology
• Autoimmunity

Background:

• Heart failure (HF) is linked to inflammation, with cardiac stress in pressure overload (PO)-induced HF activating adaptive immunity.
• This study investigates if PO-HF meets autoimmunity criteria: necessity and sufficiency of the adaptive immune response, and identification of self-antigens.
• The hypothesis posits that an antigen-specific response can be manipulated via a tolerizing vaccine to mitigate PO-HF severity.

Purpose of the Study:

• To determine if the adaptive immune response is sufficient to induce PO-HF.
• To identify novel cardiac self-antigens driving the autoimmune response in PO-HF.
• To develop and test a tolerizing vaccine for preventing PO-HF severity.

Main Methods:

• Lymphocyte and serum transfer experiments assessed the sufficiency of the adaptive response in inducing disease.
• A novel pipeline was employed to identify self-antigens responsible for the immune response.
• Mice were immunized with novel antigens, and responses in human HF patients were analyzed. An oral tolerance protocol was used for preventive protection.

Main Results:

• PO-HF partially fulfills autoimmunity criteria, with identified cardiac self-antigens capable of inducing cardiac dysfunction.
• A tolerizing vaccine formulation using these antigens preemptively reduced PO-HF severity.
• The vaccine induced effector regulatory T cells, significantly reducing systolic dysfunction, inflammation, and T-cell expansion.

Conclusions:

• PO-HF is triggered by hemodynamic stress, initiating an autoimmune-like response against cardiac self-antigens.
• These identified antigens can be used in an oral tolerization protocol to act as a protective vaccine against future PO-HF.
• This approach offers a novel strategy for preventing or reducing the severity of pressure overload-induced heart failure.